This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gu, D.-l. Articles by Pierce, G. F. Search for Related Content PubMed PubMed Citation Articles by Gu, D.-l. Articles by Pierce, G. F.

Fibroblast Growth Factor 2 Retargeted Adenovirus Has Redirected Cellular Tropism: Evidence for Reduced Toxicity and Enhanced AntitumorActivity in Mice

Selective Genetics, Inc., San Diego, California 92121 [D. G., A. M. G., M. A. P., J. D., W. Y., M. D., D. K. H., B. A. S., A. B., S. E. A., G. F. P.], and Gene Therapy Program, University of Alabama at Birmingham, Birmingham, Alabama 35294 [D. T. C., J. T. D.]

Adenovirus (Ad) have been used as vectors to deliver genes to a wide variety of tissues. Despite achieving high expression levels in vivo, Ad vectors display normal tissue toxicity, transient expression, and antivector immune responses that limit therapeutic potential. To circumvent these problems, several retargeting strategies to abrogate native tropism and redirect Ad uptake through defined receptors have been attempted. Despite success in cell culture, in vivo results have generally not shown sufficient selectivity for target tissues. We have previously identified (C. K. Goldman et al., Cancer Res., 57: 1447–1451, 1997) the fibroblast growth factor (FGF) ligand and receptor families as conferring sufficient specificity and binding affinity to be useful for targeting DNA in vivo. In the present studies, we retargeted Ad using basic FGF (FGF2) as a targeting ligand. Cellular uptake is redirected through high-affinity FGF receptors (FGFRs) and not the more ubiquitous lower-affinity Ad receptors. Initial in vitro experiments demonstrated a 10- to 100-fold increase in gene expression in numerous FGFR positive (FGFR⁺) cell lines using FGF2-Ad when compared with Ad. To determine whether increased selectivity could be detected in vivo, FGF2-Ad was administered i.v. to normal mice. FGF2-Ad demonstrates markedly decreased hepatic toxicity and liver transgene expression compared with Ad treatment. Importantly, FGF2-Ad encoding the herpes simplex virus thymidine kinase (TK) gene transduces Ad-resistant FGFR⁺ tumor cells both ex vivo and in vivo, which results in substantially enhanced survival (180–260%) when the prodrug ganciclovir is administered. Because FGFRs are up-regulated on many types of malignant or injured cells, this broadly useful method to redirect native Ad tropism and to increase the potency of gene expression may offer significant therapeutic advantages.

This article has been cited by other articles:

				J. L. Martinez-Torrecuadrada, L. H. Cheung, P. Lopez-Serra, R. Barderas, M. Canamero, S. Ferreiro, M. G. Rosenblum, and J. I. Casal Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis Mol. Cancer Ther., April 1, 2008; 7(4): 862 - 873. [Abstract] [Full Text] [PDF]

				M. L.M. Lamfers, S. Idema, L. Bosscher, S. Heukelom, S. Moeniralm, I. H. van der Meulen-Muileman, R. M. Overmeer, P. van der Valk, V. W. van Beusechem, W. R. Gerritsen, et al. Differential Effects of Combined Ad5-{Delta}24RGD and Radiation Therapy in In vitro versus In vivo Models of Malignant Glioma Clin. Cancer Res., December 15, 2007; 13(24): 7451 - 7458. [Abstract] [Full Text] [PDF]

				H.-J. Li, M. Everts, L. Pereboeva, S. Komarova, A. Idan, D. T. Curiel, and H. R. Herschman Adenovirus Tumor Targeting and Hepatic Untargeting by a Coxsackie/Adenovirus Receptor Ectodomain Anti-Carcinoembryonic Antigen Bispecific Adapter Cancer Res., June 1, 2007; 67(11): 5354 - 5361. [Abstract] [Full Text] [PDF]

				D. Hoffmann and O. Wildner Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment. Mol. Cancer Ther., February 1, 2006; 5(2): 374 - 381. [Abstract] [Full Text] [PDF]

				M. Qin, B. Escuadro, S. Sharma, and R. K. Batra Gene Transfer Mediated by Native versus Fibroblast Growth Factor-Retargeted Adenoviral Vectors into Lung Cancer Cells Am. J. Respir. Cell Mol. Biol., March 1, 2005; 32(3): 211 - 217. [Abstract] [Full Text] [PDF]

				T. Hakkarainen, A. Hemminki, A. V. Pereboev, S. D. Barker, C. K. Asiedu, T. V. Strong, A. Kanerva, J. Wahlfors, and D. T. Curiel CD40 Is Expressed on Ovarian Cancer Cells and Can Be Utilized for Targeting Adenoviruses Clin. Cancer Res., February 1, 2003; 9(2): 619 - 624. [Abstract] [Full Text] [PDF]

				C. J. A. Ring Cytolytic viruses as potential anti-cancer agents J. Gen. Virol., March 1, 2002; 83(3): 491 - 502. [Abstract] [Full Text] [PDF]

				V. W. van Beusechem, J. Grill, D. C. J. Mastenbroek, T. J. Wickham, P. W. Roelvink, H. J. Haisma, M. L. M. Lamfers, C. M. F. Dirven, H. M. Pinedo, and W. R. Gerritsen Efficient and Selective Gene Transfer into Primary Human Brain Tumors by Using Single-Chain Antibody-Targeted Adenoviral Vectors with Native Tropism Abolished J. Virol., February 22, 2002; 76(6): 2753 - 2762. [Abstract] [Full Text] [PDF]

				J. Kim, T. Smith, N. Idamakanti, K. Mulgrew, M. Kaloss, H. Kylefjord, P. C. Ryan, M. Kaleko, and S. C. Stevenson Targeting Adenoviral Vectors by Using the Extracellular Domain of the Coxsackie-Adenovirus Receptor: Improved Potency via Trimerization J. Virol., February 15, 2002; 76(4): 1892 - 1903. [Abstract] [Full Text] [PDF]

				E. A. Kashentseva, T. Seki, D. T. Curiel, and I. P. Dmitriev Adenovirus Targeting to c-erbB-2 Oncoprotein by Single-Chain Antibody Fused to Trimeric Form of Adenovirus Receptor Ectodomain Cancer Res., January 1, 2002; 62(2): 609 - 616. [Abstract] [Full Text] [PDF]

				D. A. Einfeld, R. Schroeder, P. W. Roelvink, A. Lizonova, C. R. King, I. Kovesdi, and T. J. Wickham Reducing the Native Tropism of Adenovirus Vectors Requires Removal of both CAR and Integrin Interactions J. Virol., December 1, 2001; 75(23): 11284 - 11291. [Abstract] [Full Text]

				K. Inoue, P. Perrotte, C. G. Wood, J. W. Slaton, P. Sweeney, and C. P. N. Dinney Gene Therapy of Human Bladder Cancer with Adenovirus-mediated Antisense Basic Fibroblast Growth Factor Clin. Cancer Res., November 1, 2000; 6(11): 4422 - 4431. [Abstract] [Full Text] [PDF]